About Get Ipamorelin: An Independent Research Digest on Ipamorelin
What this site is
Get Ipamorelin is an independent editorial project that publishes summaries of the peer-reviewed research literature on Ipamorelin. We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science. The word "get" in the domain is editorial framing — a stance toward getting at the literature — not an offer to supply or sell anything. There is no checkout here and there never will be.
How we choose what to cover
This digest is organized around the gut-motility and ghrelin-axis side of the ipamorelin record, because that is where the compound's clinical program actually ran and where its mechanism is most distinctive. We lead with numbers — the swine GH ED50 of 2.3 nmol/kg [1], the ~2-hour human half-life [2], the Phase 2 endpoint that missed [3] — and we pin every quantitative claim to the study that produced it. When the strongest available evidence for a caution comes from a related receptor-class compound rather than ipamorelin itself, we say so at the point we cite it. We do not fill gaps with marketing language, and we surface the human-data gaps as plainly as the findings.
What we will not do
We do not recommend human doses, we do not tell anyone what to take, and we do not present anecdote as proof. Community-reported effects are labeled anecdotal and kept separate from cited research. We name no competitor products and use only generic compound names. We do not invent studies, authors, or numbers — if a claim is not in the cited literature, it is not on this site. Ipamorelin is not an approved drug, and nothing here should be read as encouraging its use; this is a record of what the research has measured, for readers who want that record honestly assembled.